A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer

Clinical Trial Details

This clinical trial is for men and women who have completed all the requirements for a corresponding parent treatment study of AAA617.

In this study, participants will need to visit the study doctor about 2 times per year (every 6 to 8 months) which will include having routine blood and urine testing done at each visit.

Participation is expected to last up to 10 years from the first dose of AAA617 received on the parent treatment study.

Key Eligibility:

Open to men and women above the age of 18 who have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer.
Participants must be able to complete all investigational examinations.

Detailed eligibility will be reviewed when you contact the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

646-962-2072
guonc@med.cornell.edu

Primary Investigator(s)

Scott T. Tagawa, MD, MS

Protocol ID(s)

Weill Cornell Medicine IRB #:

2404027323

ClinicalTrials.gov:

NCT05803941

Status

Open to Enrollment

Age Group

Adult

Disease

Prostate Cancer